Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.

Liver international : official journal of the International Association for the Study of the Liver - 1 Jul 2010

Kim Hong Joo, Park Dong Il, Park Jung Ho, Cho Yong Kyun, Sohn Chong Il, Jeon Woo Kyu, Kim Byung Ik

Abstract excerpt

BACKGROUND AND AIMS: There has been no study comparing the clinical efficacy of clevudine and entecavir in antiviral-naïve patients with chronic hepatitis B (CHB). METHODS: A total of 128 antiviral-naïve CHB patients were included to receive clevudine 30 mg (n=55) or entecavir 0.5 mg (n=73) once daily for a mean follow-up period of 18.4 months. RESULTS: Thirty-three (60.0%) in the clevudine group and 40 (54.8%)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Guanine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Kaplan-Meier Estimate

Share to Muscular Diseases

Share to Republic of Korea

Share to Viral Load

Source

Identifiers

PMID: 20408946
DOI: 10.1111/j.1478-3231.2010.02245.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.PMID 20408946Read ↗

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.Semantic proximity Read ↗

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].Semantic proximity Read ↗

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.Semantic proximity Read ↗

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.Semantic proximity Read ↗

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.Semantic proximity Read ↗

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

[Entecavir].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.